Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

@article{Jagannath2005BortezomibTA,
  title={Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.},
  author={Sundar Jagannath and Brian G. M. Durie and Jeffrey Wolf and Elber S Camacho and David Irwin and Jose Lutzky and Marti McKinley and Eli Gabayan and Amitabha Mazumder and David P. Schenkein and John C Crowley},
  journal={British journal of haematology},
  year={2005},
  volume={129 6},
  pages={776-83}
}
Bortezomib, as a single agent and in combination with dexamethasone, was examined as first-line treatment in 32 consecutive patients with untreated symptomatic multiple myeloma. Patients received bortezomib 1.3 mg/m(2) for a maximum of six 3-week cycles; oral dexamethasone 40 mg was added if a less than partial response (PR) was achieved after two cycles or a less than complete response (CR) was achieved after four cycles. The response rate (CR + PR) was 88%, with undetectable paraprotein (CR… CONTINUE READING